Cellular Biomedicine Group Inc (NASDAQ:CBMG) insider Yihong Yao acquired 4,167 shares of the firm’s stock in a transaction dated Friday, December 22nd. The stock was bought at an average price of $12.00 per share, with a total value of $50,004.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.
Cellular Biomedicine Group Inc (NASDAQ CBMG) opened at $19.65 on Friday. Cellular Biomedicine Group Inc has a 1-year low of $5.05 and a 1-year high of $22.40. The company has a market capitalization of $252.18, a PE ratio of -11.42 and a beta of 2.59.
A number of institutional investors have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Cellular Biomedicine Group during the third quarter worth about $107,000. Susquehanna International Group LLP bought a new position in Cellular Biomedicine Group during the second quarter worth about $320,000. Finally, Goldman Sachs Group Inc. bought a new position in Cellular Biomedicine Group during the second quarter worth about $540,000. Institutional investors and hedge funds own 4.03% of the company’s stock.
Separately, BidaskClub upgraded Cellular Biomedicine Group from a “hold” rating to a “buy” rating in a report on Wednesday.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/01/13/cellular-biomedicine-group-inc-cbmg-insider-yihong-yao-acquires-4167-shares.html.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company’s technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China.
Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.